Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma
Conclusion A safe and tolerable dosing regimen was established for combination everolimus/panobinostat therapy with myelosuppression as the major DLT. This therapeutic pairing did not appear to improve clinical outcomes in our group of patients with advanced ccRCC. There was differential expression of miR-605 that correlated with treatment response. Clinical trial information: NCT01582009.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Drugs & Pharmacology | Investigational New Drugs | Kidney Cancer | Renal Cell Carcinoma | Study | Thrombocytopenia | Toxicology